LIPLASOME PHARMA ApS: Financial statements 2021
CVR: 29428514
Source: annual report 2021, Danish Business Authority
01/01/2021 – 31/12/2021
LIPLASOME PHARMA ApS (CVR 29428514) has filed annual accounts for 2021. In 2021, the company reported a gross profit of DKK 108,000 and a net result of DKK 98,000 compared with DKK -156,000 the year before. Equity in the 2021 report amounted to DKK 175,000. The solvency ratio was 94.1%.
- Gross Profit
- DKK 108,000
- Profit/Loss
- DKK 98,000
- Equity
- DKK 175,000
- Total Assets
- DKK 186,000
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2021 | - | 108 t. | 98 t. | 175 t. | - |
| 2020 | - | -133 t. | -156 t. | 77 t. | - |
| 2019 | - | -81 t. | -33.6 mio. | 233 t. | - |
| 2018 | - | -61 t. | -54 t. | 33.8 mio. | - |
| 2017 | - | -65 t. | -55 t. | 33.8 mio. | 0 |
Official annual report
Find more companies like LIPLASOME PHARMA ApS
Build lead lists with filters on industry, geography, size and financials — and export straight to Excel.
Try the lead list generatorEvents in 2021
LIPLASOME PHARMA ApS has published its annual report for 2020. Gross profit came to DKK -133,000, and the net result was DKK -156,000.
About LIPLASOME PHARMA ApS
LIPLASOME PHARMA ApS is a Danish company of the type Anpartsselskab based in Vejle, founded in 2006. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named BIO-BEDST ApS. The management consists of Hans-Henrik Horsted Eriksen. The board consists of John Riis Mortensen (chair), Hans-Henrik Horsted Eriksen and Sanjay Kumar Sehgal. The company is owned by BAGGER-SØRENSEN & CO. A/S. The company has 0 employees (2016). In 2025, the company reported a gross profit of DKK -28,000 and a net result of DKK 62,000 compared with DKK -36,000 the year before. Equity in the 2025 report amounted to DKK 2,377,000.